Gálvez Rafael, Ribera Victoria, González-Escalada José Ramón, Souto Alicia, Cánovas María Luz, Castro Andrés, Herrero Begoña, de Los Angeles Maqueda María, Castilforte Matilde, Marco-Martínez José Javier, Pérez Concepción, Vicente-Fatela Lorenza, Md Consuelo Nieto, Orduña Maria José, Padrol Anna, Reig Enrique, Carballido Joaquín, Cózar José Manuel
Pain and Palliative Care Unit, Hospital Universitario Virgen de las Nieves, Granada, Spain;
Patient Prefer Adherence. 2008 Feb 2;2:215-24. doi: 10.2147/ppa.s2314.
A multi-centered observational study evaluated the efficacy of zoledronic acid for improving pain and mobility, and preventing skeletal-related events (SRE) (fracture, spinal compression, pain-relieving radiotherapy), in patients with prostate cancer and bone metastasis.
Males (n = 218) with prostate cancer and bone metastasis undergoing oncologic therapy received zoledronic acid (4 mg iv/month) for 6 months. Parameters evaluated were: 1) pain and movement after 2 consecutive doses; 2) quality of life; 3) SRE incidence and time-to-appearance. Medication tolerance and treatment satisfaction were assessed using a questionnaire.
A total of 170 that matched all the inclusion criteria (78%) out of 218 were evaluable for efficacy. There was a measurable statistically significant reduction in pain at rest and on movement as well as an improvement in the quality of life compared with baseline. Best results were obtained with early treatment. Overall incidence of bone events was 11.2%. Of the 212 patients (97.2%) evaluable for safety, 16% suffered adverse events and 66% expressed satisfaction with the treatment
Zoledronic acid is effective for reducing pain, improving mobility, and increasing the quality of life in patients with prostate cancer with bone metastasis. Its easy administration and good tolerability make zoledronic acid one of the principal therapeutic tools in the management of patients with pain associated with bone metastasis from prostate cancer.
一项多中心观察性研究评估了唑来膦酸对改善前列腺癌骨转移患者的疼痛和活动能力以及预防骨相关事件（SRE）（骨折、脊柱压缩、止痛放疗）的疗效。
218例接受肿瘤治疗的前列腺癌骨转移男性患者接受唑来膦酸（4mg静脉注射/月）治疗6个月。评估的参数包括：1）连续2剂后的疼痛和活动情况；2）生活质量；3）SRE发生率和出现时间。使用问卷评估药物耐受性和治疗满意度。
218例中共有170例符合所有纳入标准（78%）可进行疗效评估。与基线相比，静息和活动时的疼痛有统计学意义的显著减轻，生活质量得到改善。早期治疗效果最佳。骨事件的总体发生率为11.2%。在212例可评估安全性的患者（97.2%）中，16%发生不良事件，66%对治疗表示满意。
唑来膦酸对减轻前列腺癌骨转移患者的疼痛、改善活动能力和提高生活质量有效。其易于给药和良好的耐受性使唑来膦酸成为治疗前列腺癌骨转移相关疼痛患者的主要治疗工具之一。
